BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Chiesi snags on-demand HAE drug in $1.9B Kalvista buy
In its largest acquisition to date, Chiesi Group is buying Kalvista Pharmaceuticals Inc. for $27 per share, a roughly 40% premium to the previous day’s closing price,...

More in BioWorld

BioWorld Science

Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...

More in BioWorld Science

A closer look

Psychedelic space expanding on Trump’s EO
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a surge in...

More in A closer look

BioWorld Asia

Sun Pharma to acquire Merck spinoff Organon for $11.75B
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.